Abstract
The prevalence of Alzheimer's disease (AD) has been increasing worldwide due to the aging population, placing a substantial burden on both society and families. To date, the underlying pathogenesis of AD has not been comprehensively elucidated, and advancements in drug development for this disease have been relatively slow. Astrocytes are crucial for maintaining the homeostasis of the brain microenvironment. Astrocyte dysfunction has been closely linked to AD onset and progression. The Rac1 protein, which belongs to the Rho GTPase family, exhibits hyperactivation in the astrocytes of AD model mice. Nevertheless, the exact role of Rac1 in the pathogenesis of AD remains ambiguous. The TLR4/Rac1/NLRP3 signaling pathway is involved in diverse cellular activities and inflammatory responses and plays a significant role in the AD neuroinflammatory process. This review explores the mechanism of action of Rac1 in astrocytes in the context of AD and how the TLR4/Rac1/NLRP3 pathway influences the pathological process, offering novel theoretical foundations and potential therapeutic targets for preventing and treating this disease.
Introduction
Alzheimer's disease (AD) is traditionally defined by amyloid-beta (Aβ) plaques and tau tangles. However, the role of non-neuronal support cells, particularly astrocytes, is increasingly recognized as a critical driver of disease progression. In the AD brain, astrocytes transition from a homeostatic state to a "reactive" state, characterized by morphological changes and the release of inflammatory mediators.
Central to this transformation is the Rac1 protein, a Rho GTPase that serves as a master regulator of the cellular cytoskeleton. While Rac1 hyperactivation is a known feature of AD models, its specific molecular contributions to neuroinflammation and synaptic loss are only now being fully mapped.
Molecular Mechanisms of Astrocytic Rac1
The Shape-Shifting Astrocyte
Rac1 hyperactivation triggers significant physical transformations in astrocytes. Reactive astrocytes exhibit enlarged cell bodies and more complex, branched processes. These structural alterations fundamentally impair the astrocyte's ability to provide metabolic support and maintain synaptic homeostasis, contributing to the cognitive decline seen in AD.
The TLR4/Rac1/NLRP3 Inflammatory Axis
A key pathway identified in AD progression involves the interaction between Aβ plaques and Toll-like receptor 4 (TLR4) on the astrocyte surface. This binding activates Rac1, which subsequently stimulates the production of reactive oxygen species (ROS). These ROS act as secondary messengers to activate the NLRP3 inflammasome, leading to the release of pro-inflammatory cytokines such as IL-1β. This creates a self-perpetuating cycle of neuroinflammation and further Aβ accumulation.
Pathological Consequences
Metabolic and Synaptic Dysfunction
Dysregulated Rac1 activity disrupts the astrocyte-neuron lactate shuttle, starving neurons of essential energy. Furthermore, it impairs the clearance of glutamate from the synaptic cleft. The resulting glutamate accumulation leads to excitotoxicity and the loss of dendritic spines, directly impairing synaptic plasticity and memory.
Vascular Impairment
Aβ-induced Rac1 activation also impacts the cerebral vasculature by promoting the overproduction of endothelin-1 (ET-1), a potent vasoconstrictor. The resulting sustained constriction reduces cerebral blood flow, hindering the brain's ability to wash away toxic metabolites and exacerbating the disease state.
Therapeutic Potential and Future Directions
Targeting the TLR4/Rac1/NLRP3 pathway holds significant therapeutic promise. In animal models, pharmacological inhibition of Rac1 has been shown to reduce NLRP3 inflammasome activation, improve spatial memory, and restore synaptic markers.
Future research should prioritize humanized models, such as cerebral organoids, and the development of real-time biosensors to monitor Rac1 activity in vivo. Additionally, using Rac1-GTP levels as a biomarker could enable precision medicine approaches, allowing for targeted therapy in patients with specific hyperactive profiles.
Summary updated